#USA #Minneapolis #Vascular Health #VentureMed Group #FLEX Vessel Prep

VentureMed Group Secures $28 Million Series C Funding

VentureMed Group, Inc., a leader in medical devices specializing in vascular preparation and access management technologies, has successfully concluded a Series C funding round amounting to $28 million. This financing, spearheaded by S3 Ventures and supported by existing investors like Endeavour Vision, aims to accelerate the commercial adoption of the FLEX Vessel Prep™ system and broaden its indications.

Denis Harrington, the company’s President and CEO, expressed his gratitude towards current investors while welcoming new partners to their consortium. He emphasized that this significant funding underlines the investors' confidence in the FLEX Vessel Prep™ system and VentureMed's mission to strengthen its position in the global vascular care landscape.

The funding aims not only to enhance commercial infrastructure but also to advance VentureMed's clinical program and support the development of new products, including applications in adjacent vascular environments. Brian R. Smith, managing director of S3 Ventures, highlighted that VentureMed addresses a persistent challenge in vascular access with a transformative technology, reflecting a shared mission to provide innovative treatments for those in need.

Globally, vascular diseases are increasingly burdensome, largely driven by the rising rates of obesity, diabetes, and hypertension. In the U.S. alone, peripheral artery disease (PAD) impacts over 20 million individuals, while over 200 million are affected worldwide. Stenosis and vascular dysfunction are critical contributors to vascular access failure in dialysis patients. The FLEX system was designed to improve vascular distensibility, minimize trauma, and promote better long-term outcomes.

Dr. Ari Kramer, a general surgeon at Spartanburg Medical Center, noted that lesion preparation is quickly becoming one of the most vital procedures for improving patient outcomes. He stated that the FLEX VP system pioneers arteriovenous access interventions. This funding represents a significant milestone as the company works to gather additional clinical evidence and expand indications further.

FLEX, which has received 510(k) clearance from the FDA and achieved CE mark approval, along with a specific HCPCS code (C1600) in the U.S., is positioned to redefine vascular preparation and potentially expand treatment options globally.

Alexander Schmitz, a partner at Endeavour Vision, remarked that the cycle of repeated stenosis and interventions in vascular disease poses a considerable burden on patients and healthcare systems alike. A technology that lessens the need for re-interventions not only improves outcomes but also aligns with the shift toward value-based care.

About VentureMed Group

VentureMed Group, Inc., headquartered in Minnesota, is a pioneering medical device company dedicated to developing endovascular solutions for arteriovenous (AV) access and treating peripheral artery disease (PAD). The company's signature technology, the FLEX Vessel Prep™ System, is designed to optimize vascular preparation through its patented Kinetic Endovasular Microincision Creation (KEMIC) technology. Unlike traditional balloon methods that apply static pressure, KEMIC utilizes controlled movement and dynamic vessel apposition to create precise, long microincisions. This unique mechanism facilitates luminal gain, enhances drug absorption in combination therapy, and can reduce vascular trauma, thereby decreasing the risk of re-stenosis. For more information, visit VentureMedgroup.com.

References:
1. Allison M.A. et al. Circulation. 2023;148286–296.

Media Contact:
Tom Michals
Email: [email protected]
Phone: +1(763) 951-0280